MAP2K7 and mantle cell lymphoma: This complements previous studies in DLBCL and MCL cell lines and a DLBCL mouse model that suggested potentiation of ibrutinib’s viability decreasing effects by downregulation of p-ERK-1/2 through inhibition of the MEK/ERK/AKT pathway [63].